Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET
Company Participants
Rick Winningham - Chief Executive Officer
Rhonda Farnum - Chief Business Officer
Rick Graham - Senior Vice President of Research and Development
Aziz Sawaf - Chief Financial Officer
Conference Call Participants
David Risinger - SVB Securities
Jingming Chen - Evercore
Divya Rao - TD Cowen
Operator
Ladies and gentlemen, good afternoon. I’d like to welcome everyone to the Theravance Biopharma First Quarter 2023 Conference Call. [Operator Instructions] Also, today’s conference call is being recorded.
And now I’d like to turn the call over to Rick Winningham, Chief Executive Officer. Please go ahead.
Rick Winningham
Good afternoon. And thank you for joining the Theravance Biopharma first quarter 2023 earnings conference call.
On Slide 2 I’d like to remind you to that this call will contain forward-looking statements that involve risks and uncertainties, including statements about our development pipeline, expected benefits of our products, anticipated timing of clinical trials, regulatory filings and expected financial results. Information concerning factors that could cause results to differ materially from our forward-looking statements is described further in our filings with the SEC.
Turning your attention to Slide 3, I’m joined today by Rhonda Farnum, Chief Business Officer; Rick Graham, Senior Vice President of Research and Development; and Aziz Sawaf, Chief Financial Officer.
On Slide 4, I’d like to begin my presentation by focusing your attention on Theravance’s immediate future. Those of you who are familiar with the company recognize the tremendous work that our team and partners have done to bring the organization to this point. Through a combination of perseverance and resilience, we’re now in a position to focus our energies behind two key initiatives, capitalizing on the tremendous opportunity we have to grow YUPELRI and executing on an unambiguous regulatory pathway for ampreloxetine in multiple systems atrophy patients with symptomatic nOH. These are reflected in the 2023 targets we outlined in our last quarterly call and I am pleased to share with you the progress that we’ve achieved today.
On Slide 5, beginning with YUPELRI, our team in collaboration with Viatris, turned in a solid quarter with sales up 8% year-over-year. As we previously discussed, there are many COPD patients not well controlled on their existing therapy, a good benefit from either the addition of or switching to YUPELRI. We bring a coordinated approach to reducing the barriers that prevent patients from receiving YUPELRI and or working diligently to translate this into tangible results. Importantly, we know our hospital customers comprehensively and we meet them with solutions that fit their individual needs.